Overview

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Status:
Recruiting
Trial end date:
2022-10-11
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Ranibizumab